Navigation Links
KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation
Date:4/8/2008

Settlement in Principle Would Bring To Close Derivative Lawsuit Filed in

October 2006

ST. LOUIS, April 8, 2008 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical products, announced today that it has reached a comprehensive settlement agreement in principle with the plaintiffs in a derivative lawsuit relating to the Company's historic stock option granting practices, subject to limited confirmatory discovery and court approval. Fees and costs awarded by the Court are expected to be covered by insurance.

Upon final Court approval of the settlement agreement, all private securities litigation pending against the Company regarding the stock option matter will be resolved.

"Upon its finalization, the settlement of this litigation will be another step, along with the recent filing of the Company's Form 10-Q's and Form 10-K for Fiscal 2007, towards putting the entire option issue behind us," stated Marc S. Hermelin, Chairman of the Board.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology- distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate website at http://www.kvpharmaceutical.com.

Safe Harbor

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans", "expects", "aims", "believes", "projects", "anticipates", "commits", "intends", "estimate", "will", "should", "could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, statements about the Company's strategy for growth, product development, product launches, regulatory approvals, resolution of litigation and issues pertaining to the Company's historic stock option granting processes, market position, market share increases, acquisitions, revenues, expenditures and other financial results, are forward- looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (6) reliance on key strategic alliances; (7) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (8) the regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of predicting international regulatory approval, including timing; (11) the difficulty of predicting the pattern of inventory movements by the Company's customers; (12) the impact of competitive response to the Company's sales, marketing and strategic efforts; (13) risks that the Company may not ultimately prevail in litigation; (14) completion of the Company's financial statements for the first, second and third quarters of fiscal 2008; (15) actions by the Securities and Exchange Commission and the Internal Revenue Service with respect to the Company's stock option grants and accounting practices; (16) the risks detailed from time to time in the Company's filings with the Securities and Exchange Commission; and (17) the impact of credit market disruptions on the fair value of auction rate securities that we have acquired as short-term investments.

This discussion is by no means exhaustive, but is designed to highlight important factors that may impact the Company's outlook. We are under no obligation to update any of the forward-looking statements after the date of this release.


'/>"/>
SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
2. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
3. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
4. China Shenghuo Pharmaceutical Holdings, Inc. to Present at Brean Murray Carret & Co. Mainland China Investor Tour
5. Breckenridge Pharmaceutical Enters Agreement With Helm AG (Hamburg, Germany) to Develop Additional ANDA Project
6. ISTA Pharmaceuticals Engages Cowen as Financial Advisor
7. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
8. Benda Pharmaceutical Reports Fourth Quarter and Full Year 2007 Financial Results
9. Pharmaceutical Strategic Initiatives Adds Anne Sexton, MD, MS to Management Team
10. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
11. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... MN (PRWEB) , ... May 31, 2016 , ... DDL, ... the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO 594-2 ... common means of achieving a leak-free connection between two medical devices (e.g. a syringe ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the multiple awards ... is home to Ontario’s leading day spa and one of Canada’s few accredited 5 ... a unique concept to combine spa services with hair and beauty services ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education Foundation (OREF) ... David G. Lewallen, MD, began his term as president in March, succeeding John J. ... is OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, corporate development, ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 Inc. , Each ... series of research reports evaluating these innovative vendors and their products and services. ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Super Powder, a ... to on the go individuals and dedicated athletes, continues to transform the nutritional supplement ... with whey, pea and milk protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
Breaking Medicine Technology: